KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.

导出原文传递

翻译打印收藏纠错

第一作者： Disha,Malani

第一单位： Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. disha.malani@helsinki.fi.

作者： Disha,Malani ^[1] ; Bhagwan,Yadav ^[2] ; Ashwini,Kumar ^[2] ; Swapnil,Potdar ^[2] ; Mika,Kontro ^[2] ; Matti,Kankainen ^[3] ; Komal K,Javarappa ^[4] ; Kimmo,Porkka ^[3] ; Maija,Wolf ^[2] ; Tero,Aittokallio ^[3] ; Krister,Wennerberg ^[4] ; Caroline A,Heckman ^[2] ; Astrid,Murumägi ^[2] ; Olli,Kallioniemi ^[5]

作者单位： Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. disha.malani@helsinki.fi. ^[1] Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. ^[2] Hematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland. ^[3] Department of Hematology, University Hospital Comprehensive Cancer Center, Helsinki, Finland. ^[4] Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, and Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway. ^[5] Biotech Research & Innovation Centre, BRIC and Novo Nordisk Foundation Center for Stem Cell Biology, DanStem, University of Copenhagen, Copenhagen, Denmark. ^[6] Science for Life Laboratory, Department of Oncology and Pathology, Karolinska Institutet, Solna, Sweden. ^[7]